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Abstract
Epithelial ovarian cancer (EOC) comprises approximately 90% of ovarian cancers and arises from the surface
epithelium. Typical treatment of EOC involves cytoreductive surgery combined with chemotherapy. More recent
therapies have targeted the tumor vasculature using antiangiogenic compounds such as thrombospondin-1 (TSP-1).
TSP-1 mimetic peptides such as ABT-510 have been created and have been in various clinical trials. We have previ-
ously shown that ABT-510 reduces abnormal vasculature associated with tumor tissue and increases the presence of
mature blood vessels. It has been hypothesized that treatmentwith antiangiogenic compoundswould allow increased
delivery of cytotoxic agents and enhance treatment. In this study, we evaluated the potential role of ABT-510 and
various chemotherapeutics (cisplatin and paclitaxel) on tumor progression, angiogenesis, and the benefits of combi-
national treatments on tissue uptake and perfusion using an orthotopic syngeneic mouse model of EOC. Animals
were treated with ABT-510 (100mg/kg per day) alone or in combinationwith cisplatin (2mg/kg per 3 days) or paclitaxel
(10mg/kg per 2 days) at 60 days after tumor induction. Radiolabeled and fluorescently labeled paclitaxel demonstrated
a significant increase in tumor uptake after ABT-510 treatment. Combined treatment with ABT-510 and cisplatin or
paclitaxel resulted in a significant increase in tumor cell and tumor endothelial cell apoptosis and a resultant decrease
in ovarian tumor size. Combined treatment also regressed secondary lesions and eliminated the presence of abdomi-
nal ascites. The results from this study show that through vessel normalization, ABT-510 increases uptake of chemo-
therapy drugs and can induce regression of advanced ovarian cancer.
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Introduction
Ovarian cancer represents the most lethal gynecologic malignancy.
With an estimated 22,000 new cases and 15,000 deaths annually,
ovarian cancer is the fifth leading cause of cancer deaths among
US women [1]. Tumors of the ovary are classified and named accord-
ing to the cell type from which they originate and whether they are
benign or cancerous. There are various subtypes of EOC according
to the World Health Organization based on their histopathology [2].
Epithelial ovarian cancer (EOC) comprises approximately 90% of
ovarian cancers and is thought to arise from the surface epithelium
of the ovary [3]. Of these tumors, the most prevalent subtype of
EOC is serous adenocarcinoma, constituting approximately 68%
of EOCs. If diagnosed at early stages, the 5-year survival rate is
98% compared with only 25% at later stages of the disease [4]. Of
particular concern with this disease is that the obscure clinical signs
associated with EOC generally preclude early detection or treatment.
Conventional treatment of ovarian cancer typically involves cyto-
reductive surgery (debulking) combined with platinum- or taxol-
based chemotherapy [5]. Although this approach generally results
in primary tumor shrinkage, tumor recurrence often occurs, and
the incidence of EOC chemoresistance is very high [6]. To combat
this chemoresistance and disease recurrence, numerous alternative
therapies have been investigated including those designed to focus
on ovarian tumor vasculature.
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The concept of antiangiogenic therapy was proposed decades
ago, and it was thought that inhibiting the tumor vasculature would
induce dormancy and tumor regression. Various compounds have
since been identified for their ability to inhibit angiogenesis [7].
Thrombospondin-1 (TSP-1) was the first protein recognized as an en-
dogenous inhibitor of angiogenesis and has been investigated for its
efficacy in the treatment of various cancers [8]. For therapeutic inter-
ventions, small TSP-1 mimetic peptides have been developed. The mi-
metic ABT-510 exploits the antiangiogenic domain (second type 1
repeat) of TSP-1, activating expression of FasL, inhibiting expression
of proangiogenic factors vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor, and inducing tumor cell apoptosis [9].
ABT-510 has been tested clinically for the treatment of various
cancers alone or in combination with other cytotoxic agents, with
variable results [10–13]. In studies where ABT-510 was used as com-
bination treatment, it was found that ABT-510 was well tolerated
and that any adverse effects observed were consistent with those of
chemotherapeutics on their own [14–16].
In this study, we evaluated the antiangiogenic mimetic peptide
ABT-510 at various stages of disease and in combination with chemo-
therapeutics to determine the effect on epithelial ovarian tumors in a
mouse model of the disease. Single-agent therapies have limited suc-
cess in cancer treatment, and we hypothesize that combinational
treatments of ABT-510 with cytotoxic agents may be more effective.
Animals in this study were treated with ABT-510 alone or in com-
bination with cisplatin or paclitaxel to determine the potential clin-
ical effectiveness of these agents.
Materials and Methods
Cell Line
Murine surface epithelial cells were generously donated by Drs. Roby
and Terranova (Kansas State University, KS) [17]. The ID8 cell line was
cultured in Dulbecco’s modified Eagle medium (Gibco, Burlington,
Ontario, Canada) supplemented with 10% FBS and 1% antibiotic-
antimycotic (Gibco) and used for subsequent in vivo experiments.
Animal Model
We have previously generated an orthotopic, syngeneic mouse model
of EOC that closely replicates ovarian serous adenocarcinoma in
women [18]. Briefly, 1.0 × 106 ID8 cells in 5 μl of PBS are injected
directly under the ovarian bursa of C57Bl6 mice. Because the ID8
cells were derived from a C57Bl6 mouse, this syngeneic model allows
for an intact immune system and orthotopic placement of the epi-
thelial cells in their normal microenvironment. In this model, mice
develop large primary tumors, numerous secondary peritoneal le-
sions, and abdominal ascites approximately 90 days after tumor induc-
tion. Primary tumors were collected and measured for subsequent
analysis, and secondary tumors were assessed based on a lesion scoring
system as previously described [18].
Drugs
ABT-510 was obtained from Abbott Laboratories (Abbott Park,
IL). Cisplatin (Calbiochem, Gibbstown, NJ) and paclitaxel (Sigma-
Aldrich, Oakville, Ontario, Canada) were purchased commercially.
Tumor induction was performed as described previously [18], and
tumors were allowed to grow for 60 days before ABT-510, cisplatin
and paclitaxel individual or combination treatments began. Animals re-
ceived intraperitoneal (IP) injections of vehicle (D5W; 200 μl) alone
or containing drug (ABT-510 100 mg/kg daily, cisplatin 2 mg/kg every
3 days, paclitaxel 10 m/kg every 2 days). For quantification of ab-
dominal ascites and secondary lesions, mice were treated with a lower
dosage of paclitaxel (5 mg/kg every 2 days) alone or in combination
with paclitaxel. Cisplatin and paclitaxel were reconstituted in D5W
or 50% cremophor and 50% ethanol, respectively, just before in-
jections. The animals continued to receive IP injections of the vari-
ous agents until the control mice became moribund, which occurred
approximately 90 days after tumor induction. All animals were eu-
thanized, and serum, ascites fluid, and ovarian tissue were collected
and processed.
VEGF ELISA
Serum was collected (BD Vacutainers, Franklin Lakes, NJ) at the
time of euthanasia from ABT-510–treated animals, and the expres-
sion of VEGF was determined using sandwich enzyme-linked immu-
nosorbent assays (R&D Systems, Inc, Minneapolis, MN) according
to the manufacturer’s instructions. Briefly, serum samples were di-
luted 1:100 and added to the precoated wells. Unbound substrate
was washed away, and an enzyme-linked polyclonal antibody specific
for VEGF was added to the wells followed by subsequent washes and
addition of color substrate. Individual well absorbance was measured
at 450 nm using an EL 800 Universal Microplate Reader (Bio-Tek
Instruments, Winooski, VT).
Immunoblot Analysis
Flash-frozen primary ovarian tumors were homogenized in RIPA
buffer with protease and phosphatase inhibitors, and protein concen-
trations were determined using a DC protein assay (Bio-Rad Labora-
tories, Hercules, CA). All Western blots were performed using an
XCell II BlotModule System (Invitrogen, Burlington,Ontario, Canada).
Samples (40 μg of total protein) were reduced and subjected to SDS-
PAGEusing either 8% or 15% resolving gels. Proteins were transferred
to polyvinylidene difluoride membranes (Bio-Rad Laboratories) and
blocked at room temperature for 1 hour in 5% skim milk with Tris-
buffered Saline Tween 20. Membranes were probed for overnight at
4°C for VEGF and VEGFR2 (Santa Cruz, Burlingame, CA). After
washing with Tris-buffered Saline Tween 20, membranes were incu-
bated for 1 hour at room temperature with antirabbit immunoglobu-
lin G HRP-linked secondary antibodies (Cell Signaling Technology,
Inc., Beverly, MA). The expressions of VEGF and its receptor were
detected using Western Lightning Chemiluminescence Reagent Plus
(PerkinElmer BioSignal, Inc,Montreal,Quebec, Canada) and visualized
usingmedical x-ray film (KonicaMinoltaMedical Imaging, Inc,Wayne,
NJ). To ensure equal loading of samples, β-actin (Cell Signaling Tech-
nology) was probed for 1 hour at room temperature followed by anti-
rabbit immunoglobulin G secondary antibody for 1 hour at room
temperature. Computer-assisted densitometry was performed using
AlphaEase FC software (AlphaInnotech, San Leandro, CA), and results
were quantified and reported as integrated densitometry values relative
to β-actin.
Immunohistochemistry
Ovarian tissue was formalin-fixed and processed using a paraffin tis-
sue processor (Ventana Medical Systems, Tuscon, AZ), and 5-μm sec-
tions were cut and mounted onto slides. Sections were deparaffinized
in xylene and rehydrated in graded alcohol solutions. Immunohisto-
chemistry was performed to determine localization and expression of
the endothelial cell marker CD31 within the ovarian tissue. Endoge-
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nous peroxidase activity was inhibited using 1% hydrogen peroxide for
10 minutes at room temperature. Antigen retrieval was achieved by
immersing slides in 10 mM citrate buffer at 90°C for 12 minutes. Tis-
sues were blocked using 5% BSA for 10 minutes at room temperature
and incubated with anti-CD31 primary antibody (BD Biosciences
Pharmingen, San Diego, CA) overnight at 4°C in a humidity chamber.
The following day, sections were incubated with antimouse biotin-
ylated secondary antibody (Sigma-Aldrich Canada Ltd) for 2 hours at
room temperature. Tissues were then exposed to ExtrAvidin (Sigma-
Aldrich Canada Ltd) for 1 hour at room temperature, and antibodies
were visualized using DAB (Sigma-Aldrich Canada Ltd). Tissue was
counterstained with Carazzi’s hematoxylin, dehydrated, and mounted
on coverslips. Slides were imaged using bright field microscopy.
Evaluation of Microvessel Density and Vessel Maturity
To evaluate tumor vessel area and microvessel density, tumor sec-
tions immunostained for CD31 were imaged at a magnification of
×200, and microvessel density and blood vessel area were quantified
using Metamorph integrated morphometry software (Molecular De-
vices, Downingtown, PA). For the determination of vessel density, a
minimum of four fields of view per tissue section were used, with n =
6 per group. To evaluate blood vessel maturity, tissue sections were
subjected to immunofluorescence colocalization of CD31 and α-
smooth muscle actin (SMA). Briefly, slides were processed as above,
and the CD31 antibody was incubated for 1 hour at room temperature.
After washing in PBS, antimouse secondary antibody conjugated to
Alexa Fluor 594 (Invitrogen) was applied for 1 hour at room temper-
ature. Tissue sections were then rinsed in PBS and incubated for 1 hour
at room temperature with anti-SMA primary antibody (Fitzgerald
Industries International, Concord, MA). Secondary antibody, conju-
gated to Alexa Fluor 488 (Invitrogen), was applied for 1 hour. Tissue
sections were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) and mounted with Prolong Gold antifade (Invitrogen) and
allowed to dry overnight before image analysis with integrated mor-
phometry software (Metamorph, Burlingame, CA).Mature blood vessels
were characterized as having pericyte coverage (SMA-positive vessels)
and were quantified as a percentage of total CD31-positive vessels.
Paclitaxel Incorporation and Localization
To determine if treatment with ABT-510 would increase the uptake
of chemotherapeutic drugs, animals were injected with ID8 cells (as
outlined in our animal model) and given daily IP injections of ABT-
510 (or D5W the vehicle control) for 21 days starting at 60 days after
tumor induction. After the ABT-510 treatment, animals were injected
IP with tritiated paclitaxel (40 μCi; Moravek Biochemicals and Radio-
chemicals, Brea, CA) and were euthanized 12, 24, and 48 hours later.
Ovaries were harvested from all animals and homogenized in scin-
tillation fluid, and radioisotope was quantified with a Tri-carb Liquid
Scintillation Counter (Perkin Elmer, Waltham, MA). To localize che-
motherapy uptake, control and ABT-510–treated animals (n = 6 per
group) received an IP injection of paclitaxel conjugated to Oregon
Green 488 (Invitrogen) and were euthanized 24 hours later. The
ovaries were formalin-fixed and sectioned, and immunofluorescence
colocalization was performed to visualize blood vessels (using an anti-
CD31 antibody) and to localize paclitaxel uptake. Slides were mounted
and images were captured using an epifluorescent microscope.
Cisplatin Uptake
Accumulation of tissue platinum (Pt) was quantified using flameless
atomic absorption spectroscopy [19]. Frozen control and ABT-510–
treated tumor samples collected at 90 days after tumor induction (after
30 days of IP cisplatin treatment) were homogenized in deionized
water and evaporated at 70°C for 2 hours. Tumor tissue was then di-
gested with 200 μl of nitric acid (65%) for 2 hours at 75°C. Samples
were diluted 10× in water before injecting into the spectrometer.
Tumor and Endothelial Cell Death
To visualize and quantify tumor cell death, TUNEL assay was
performed using an In Situ Cell Death Detection Kit (Roche, Laval,
Quebec, Canada) according to the manufacturer’s instructions. Animals
received vehicle or ABT-510 treatment alone or in combination with
chemotherapy drugs cisplatin and paclitaxel as described previously.
After treatment, tissues were extracted, fixed in 10% buffered formalin,
and processed and sectioned onto glass slides. After membrane permea-
bilization, cells were washed with PBS and incubated with the TUNEL
reaction mixture (label solution and enzyme solution) for 60 minutes at
37°C in the dark. Slides were rinsed with PBS, nuclei were stained with
DAPI, and coverslips were mounted onto slides as previously described.
Negative and positive controls were generated according to the kit
instructions. All slides from immunofluorescence experiments were
visualized using a fluorescent microscope, and quantification of the
percent immunopositive cells was performed using integrated mor-
phometry software (Metamorph). For the evaluation of endothelial cell
apoptosis, CD31 immunofluorescence colocalization was performed on
tumor sections as described previously. After addition of the Alexa Fluor
594–conjugated secondary antibody, slides were washed and subjected
to theTUNELprotocol according tomanufacturer’s instructions. Tissue
sections were counterstained with DAPI, and slides were mounted.
The percentage of apoptotic endothelial cells was determined by colo-
calization with CD31 and tunnel staining and was expressed as a per-
centage of total endothelial cells.
Cancer-Associated Morbidity
At euthanasia after ABT-510 and chemotherapy drug treatment,
animals were evaluated for the presence of ascites fluid and the num-
ber of secondary lesions was scored. For secondary lesions, animals
were given a score of 0 for no lesions within the peritoneal cavity,
a score of 1 if there were 1 to 2 lesions, a score of 2 if there were
3 to 10 secondary peritoneal lesions, and a score of 3 if there were
greater than 10 lesions in the peritoneum. For ascites fluid, animals
were scored based on the presence or absence of abdominal ascites.
Statistical Analysis
All in vitro and in vivo experiments contained three replicates and
animals in each treatment group, respectively. Results from immuno-
blots, immunohistochemistry, MTT assays, ovarian tumor weights,
and blood vessel density were analyzed using Student’s t-test and
analysis of variance with a Fisher post hoc test.
Results
ABT-510 Decreases Local and Systemic Levels of VEGF
and VEGFR-2
At 60 days after tumor induction, mice received daily IP treatment
with vehicle or 100 mg/kg ABT-510 for 30 days. Western blot analysis
Neoplasia Vol. 12, No. 3, 2010 TSP-1 Improves Chemotherapy in Ovarian Cancer Campbell et al. 277
showed that ABT-510 treatment significantly (P < .05) reduced the
levels of VEGF in ovarian tumor homogenate lysates (Figure 1). Levels
of VEGFR2 were also decreased within the tumors; however, this
was not reported to be significant. ELISAs were performed on serum
samples from control mice without tumors and from tumor-bearing
mice after 30 days of treatment with vehicle or ABT-510. Vehicle-
treated mice had a three-fold increase in circulating VEGF levels
(P < .05; Figure 1). Treatment with 100 mg/kg ABT-510 significantly
decreased VEGF serum levels compared with vehicle-treated animals
(P < .05; Figure 1).
ABT-510 Alters Ovarian Tumor Vascular Morphology
Ovarian tumor tissue collected from mice treated with ABT-510
had significantly (P < .05) reduced microvessel density and tumor
blood vessel area compared with vehicle-treated controls (Figure 2,
A and B). To determine whether there was a change in vessel matu-
rity, tumor sections were costained for CD31 and SMA. ABT-510
treatment caused a significant (P < .01) increase in the percentage of
pericyte-covered mature blood vessels compared with vehicle-treated
controls (Figure 2, C and D).
ABT-510 Facilitates Vascular Uptake of Paclitaxel and
Cisplatin in Ovarian Tumors
Mice being treated IP with either vehicle or 100 mg/kg ABT-510
for 21 days received an IP injection of [3H]paclitaxel, and ovarian
tumor tissue was harvested 12, 24, and 48 hours later. Tumors from
mice treated with ABT-510 had a significant (P < .05) increase in
paclitaxel incorporation at all time points compared with vehicle-
treated controls (Figure 3A). To localize the uptake of paclitaxel, mice
received an IP injection of paclitaxel conjugated to Oregon green,
and immunofluorescence colocalization for blood vessels (CD31-
positive staining) and conjugated paclitaxel was performed. Mice
treated with ABT-510 had a greater uptake of paclitaxel compared
with controls (Figure 3B). Most of the conjugated paclitaxel was lo-
calized near the blood vessels and appeared to diffuse into the tumor
tissue from the vessels (Figure 3B). Mice being treated with both
ABT-510 and cisplatin had significantly increased (P < .05) incor-
poration of platinum of ovarian tumor tissue compared with mice
treated with cisplatin and D5W (Figure 3C ).
ABT-510 Increases the Tumor and Endothelial Cell Apoptotic
Effects of Cisplatin and Paclitaxel
After 60 days of ovarian tumor growth, mice were treated IP with
ABT-510, cisplatin, and paclitaxel, alone or in combination. Individ-
ual treatment with ABT-510, cisplatin, and paclitaxel caused a signif-
icant (P < .05) reduction in ovarian tumor weight compared with
vehicle-treated control mice (Figure 4A). When ABT-510 was com-
bined with either cisplatin or paclitaxel, there was a further reduction
(P < .05) in ovarian tumor weight, which was greater than each com-
pound alone (Figure 4A). TUNEL assay was performed to quantify
tumor cell apoptosis in response to individual or combination IP treat-
ments of ABT-510, cisplatin, and paclitaxel. ABT-510 and both che-
motherapy drugs caused a significant (P < .05) increase in tumor cell
apoptosis, and there was a further significant (P < .05) increase in tu-
mor cell apoptosis when ABT-510 was combined with either drug
(Figure 4B). To identify whether these compounds induced endothe-
lial cell death, immunofluorescence colocalization of CD31 to visualize
endothelial cells and TUNEL was performed. ABT-510, cisplatin, and
paclitaxel treatment each significantly increased ovarian tumor endo-
thelial cell death (Figure 4C). ABT-510, when combined with either
cisplatin or paclitaxel, had an additive effect, with significantly (P < .05)
Figure 1. Effect of ABT-510 on VEGF and VEGFR-2 levels. Serum and tumor tissue were collected from mice treated with vehicle (D5W)
or ABT-510 and subjected to ELISA or Western blot analysis, respectively. (A) D5W-treated mice had increased circulating VEGF com-
pared with non–tumor-bearing mice (control), whereas ABT-510 decreased VEGF levels compared with vehicle controls. (B) ABT-510
treatment at 60 days after tumor induction caused a decreased expression of VEGF protein in ovarian tumors. Bars with different letters
are statistically different, and bars with asterisks are statistically different from D5W controls.
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increased endothelial cell apoptosis compared with controls or to treat-
ment with individual compounds (Figure 4C).
ABT-510, Cisplatin, and Paclitaxel Alter
Tumor-Associated Morbidity
Mice receiving IP therapy of ABT-510, cisplatin, and paclitaxel
alone or in combination were scored for the presence of secondary
lesions within the peritoneal cavity and also for the presence of ab-
dominal ascites. Vehicle-treated controls universally had greater than
10 peritoneal secondary lesions at the time of euthanasia (Table 1).
ABT-510 treatment reduced the number of secondary lesions, as did
cisplatin and paclitaxel treatment. When ABT-510 was combined
with either cisplatin or paclitaxel, there was a complete absence of
peritoneal lesions (Table 1). Six of seven mice in D5W-treated con-
trols and five of six in ABT-510–treated mice exhibited abdominal
ascites. However, when ABT-510 was combined with either cisplatin
or paclitaxel, none of the mice had ascites fluid in the abdomen.
Discussion
The concept of antiangiogenic therapy was first proposed in the
1970s when Judah Folkman [20] highlighted the necessity of this
process for tumor growth. He hypothesized that if angiogenesis was
essential for the growth of solid tumors then diminishing this supply
might be an effective therapy. Since then, numerous agents have been
developed and tested in various cancers, which either inhibit proangio-
genic factors or upregulate antiangiogenic factors. Many studies have
focused on decreasing proangiogenic factors such as VEGF using
monoclonal antibodies. With respect to ovarian cancer, studies have
shown prolonged survival after antiangiogenic treatment [21]; how-
ever, serious toxicities have also been reported with angiogenic and
cytotoxic combinations [22–24]. More recently, compounds that in-
crease the expression of antiangiogenic compounds such as TSP-1 have
been developed. Specific TSP-1 mimetic peptides have been designed
to exploit the antiangiogenic type 1 repeats within the gene. To date,
various clinical studies have used these peptides as a single-agent ther-
apy [10–13]. In our studies, we evaluated the use of the TSP-1 mimetic
Figure 2. ABT-510 alters tumor vasculature. Ovarian tumors were collected from mice treated with vehicle or ABT-510 60 days after tumor
induction. ABT-510 caused a significant decrease in blood vessel density (A) and tumor vessel area (B). (C) ABT-510 treatment resulted in
more pericyte covered blood vessels, as evidenced by positive staining for CD31 and SMA. (D) Quantification of the percentage of mature,
pericyte-covered blood vessels. Bars with asterisks are statistically different (P < .05) compared with D5W-treated controls.
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Figure 3. Treatment with ABT-510 increases the uptake of paclitaxel and cisplatin in ovarian tumors. (A) Mice were injected IP with
tritiated paclitaxel and tumors were harvested 12, 24, and 48 hours later. Tumors from mice treated with ABT-510 (white bars) had
significantly increased drug uptake at all time points compared with D5W-treated controls (black bars). Bars with asterisks are statis-
tically different (P < .05) from vehicle controls. (B) Mice were also injected with fluorochrome-conjugated paclitaxel, and immunofluo-
rescence colocalization was performed on tumor tissue. Immunofluorescence colocalization showed that there was increased paclitaxel
incorporation (green staining) that was localized near blood vessels (red staining for endothelial cells). (C) After combined treatment with
cisplatin and ABT-510, platinum accumulation in tumor tissue was significantly increased (P < .5) compared with D5W-treated controls.
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Figure 4. ABT-510 in combination with cisplatin and paclitaxel reduces tumor size and induces tumor and endothelial cell apoptosis. (A)
After 60 days of tumor growth, mice were treated with ABT-510, cisplatin and paclitaxel, alone and in combination. All three drugs
reduced tumor size compared with D5W-treated controls. When used in combination, the drugs had an effect greater than either alone.
(B) Tumor cell apoptosis was significantly increased when ABT-510 was combined with either cisplatin or paclitaxel, as indicated by
the percentage of TUNEL (green stain)-positive cells. (C) Endothelial cell apoptosis (as indicated by CD31- [red] and TUNEL- [green]
costained cells) was significantly higher in mice treated with ABT-510 and cisplatin or paclitaxel. For all graphs, bars with different letters
are statistically different (P < .05).
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ABT-510 in combination with chemotherapeutic drugs cisplatin and
paclitaxel for the treatment of EOC. The potential for ABT-510
as an antiangiogenic therapy has been previously documented in our
laboratory in which animals were treated daily with ABT-510 imme-
diately after tumor induction, and the results demonstrated a significant
decrease in ovarian tumors, ascites fluid production, and secondary le-
sion formation [9]. In the current study, we evaluated the effects of
ABT-510 alone or in combination with chemotherapeutics at a late
stage of EOC. For these experiments, we initiated treatment at 60 days
after tumor induction, at which time an established ovarian tumor
has developed, and the animals have started to produce secondary le-
sions and ascites fluid. The morbidity seen at 60 days after tumor in-
duction replicates stage III of the disease in women, according to the
International Federation of Obstetricians and Gynaecologists classifi-
cation. It is at this stage of disease where most women are diagnosed
and treatment is initiated [25]. Animals were treated for 30 days with
ABT-510 alone or in combination with cisplatin or paclitaxel to evalu-
ate the effects of the peptide on established tumors, which is a clinically
relevant stage at which women would receive treatment.
We have previously shown that if mice are treated with ABT-510
at the time of tumor induction, ovarian tumor growth is significantly
reduced, and there is a reduction in expression of cytoprotective and
angiogenic factors such as VEGF and VEGFR-2 [9].
Results from some initial antiangiogenic trials have led some to
hypothesize that these compounds prune back the immature, disor-
ganized tumor vasculature, although leaving the normal vasculature
intact. In our study, treatment with ABT-510 reduced the tumor
blood vessel density but increased the proportion of mature, func-
tional blood vessels. As a result, the tumors were better perfused
and allowed for an increased uptake of chemotherapy drug. The
mechanism by which ABT-510 induced this vessel normalization
was through direct apoptotic effects on endothelial cells of immature
blood vessels. This apoptotic effect, coupled with the induction of
apoptosis on tumor cells, was likely responsible for the decreased tu-
mor size in mice treated with the compound. The vessel normaliza-
tion and increased tumor perfusion have led some researchers to
postulate that antiangiogenic therapy would be most effective when
used in combination with chemotherapeutics [26–28]. Indeed, in
our study, the effects of either cisplatin or paclitaxel were significantly
increased when combined with ABT-510 treatment.
It seems from the results of this study that the additive effectiveness
of ABT-510 and the chemotherapeutics was due to increased uptake
of the drugs. Animals were treated for 3 weeks with ABT-510 daily
before they were injected with radiolabeled paclitaxel. There was a sig-
nificant increase in paclitaxel incorporation within the ovaries at all
time points compared with animals that did not receive the mimetic.
Similarly, ABT-510 also facilitated an increased uptake of cisplatin in
ovarian tumor tissue. We also injected a group of animals with fluo-
rescently labeled paclitaxel to localize the cytotoxic agent in the ovarian
tumors. We found that animals pretreated with ABT-510 had in-
creased paclitaxel uptake in the perivascular areas of the tumor. This
localization suggests that the chemotherapy drug uptake was facilitated
by the normalized vasculature resulting from ABT-510 treatment. In
in vitro experiments in our laboratory, we found that treatment of ID8
cells by ABT-510 and the chemotherapy drugs alone or in combina-
tion did not affect the apoptotic effects of the compounds (data not
shown). These data suggest that the enhanced antitumor effects of
ABT-510 and the chemotherapy drugs were due to increased uptake
rather than by additive apoptotic effects on tumor cells directly. The
anti-VEGF antiangiogenic drug bevacizumab has been shown to re-
duce overall blood vessel density while simultaneously decreasing
interstitial pressure, increasing tumor tissue perfusion, and increasing
the effectiveness of radiation and chemotherapy in patients with rectal
cancer [29]. Of considerable interest is the ability of TSP-1 mimetics
to increase tissue perfusion and facilitate chemotherapy drug uptake.
Intuitively, this would suggest that by increasing the efficiency of drug
delivery, patients may require significantly lower dosages of chemother-
apy drug to receive the same or improved effects. Also, increased de-
livery of chemotherapeutic drugs to tumor cells may increase the
proapoptotic effects of these drugs, resulting in a more efficient chem-
ical debulking of the tumor and decreased drug resistance. Because ap-
proximately 90% of patients with metastatic disease succumb to the
disease for issues related to drug resistance [30], any strategy to reduce
chemotherapy drug resistance could have tremendous benefit.
The size of the primary tumors was significantly reduced in ani-
mals treated with ABT-510 and even more reduced when combined
with either cisplatin or paclitaxel. An important observation as well
was the complete absence of secondary metastatic peritoneal lesions
within the peritoneal space as well as the lack of ascites fluid when
mice were treated with the combination of ABT-510 and cisplatin or
paclitaxel. These data are significant because treatment with these
compounds was not initiated until mice were already suffering from
metastatic disease, indicating that ABT-510 treatment combined
with chemotherapy caused regression of the disease. The clinical im-
portance of these data is highlighted by the fact that most (approx-
imately 75%) women are not diagnosed with the disease until the
tumor has developed and spread within the abdomen [31].
TSP-1 seems to have important effects both on the tumor vascu-
lature as well as direct apoptotic effects on tumor cells themselves.
Trastuzumab is an effective antiangiogenic molecule that has been re-
ported to normalize tumor vasculature. Interestingly, the reported
mechanism by which trastuzumab decreases proangiogenic factor ex-
pression and induces tumor cell apoptosis is through the up-regulation
of TSP-1 [32]. Low-dose metronomic chemotherapy is known to elicit
a strong antiangiogenic influence [33,34], and increased expression of
TSP-1 is an important mediator of this effect [35].
In conclusion, we have shown that the TSP-1 mimetic peptide
ABT-510 causes tumor and endothelial cell apoptosis. The pruning
of abnormal tumor vasculature seems to leave healthier, normalized
blood vessels that facilitate uptake of chemotherapeutic drugs and
increase their effectiveness. These results suggest that combined anti-
angiogenic treatment with TSP-1 mimetics and chemotherapy drugs
may significantly improve the outcome of patients with EOC.
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